Vioxx withdrawal alarms cancer prevention researchers.
Vanchieri
Cori
C
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects; D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001168:Arthritis / Q000188:drug therapy; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D004195:Disease Models, Animal; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007783:Lactones / Q000009:adverse effects; D009369:Neoplasms / Q000517:prevention & control*; D011720:Pyrazoles; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects*; D013450:Sulfones; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D016861:Cyclooxygenase Inhibitors; D020847:Estrogen Receptor Modulators; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; D013629:Tamoxifen; C116926:rofecoxib; D000068579:Celecoxib